• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Pfizer marks another win against generic drugs

      Posted AtNewYorkBuysiness.com

      Pfizer Inc. logged another win against generic drugmaker Ranbaxy Laboratories Inc. in its battle to protect the patents of its drugs.

      A New Jersey court upheld a preliminary injunction late yesterday prohibiting India's Ranbaxy from selling a generic version of Pfizer's high blood pressure treatment, Accupril. The court also halted Israel's Teva Pharmaceutical Industries Ltd. from marketing a generic version.The ruling stems from a patent infringement case filed by Pfizer in March against the two generic drugmakers. Accupril, which had sales of $665 million last year, has patent exclusivity until 2007. Pfizer said that other "non-infringing formulations" are currently being sold in the U.S.

      Pfizer's vice chairman and general counsel, Jeff Kindler, said in a statement that the court's resolution "sends a clear message that the law does not encourage or excuse infringement of valid pharmaceutical patents by generic companies."

      The decision marks the second time this month that Pfizer won court rulings against Ranbaxy.

      Earlier this month, a court in Norway barred Ranbaxy from selling a generic form of Lipitor there, and a British court in October dismissed Ranbaxy's motion challenging a patent covering Lipitor's active ingredient. Lipitor's patent extends until 2011.

      Ranbaxy, Teva and Pfizer will still face off in the Accupril battle. The case is headed to trial in the District Court in New Jersey, where Pfizer is seeking damages for lost sales. "Ranbaxy intends to vigorously challenge infringement, validity and enforceability of the patent in further proceedings before the district court," said Jay Deshmukh, Ranbaxy vice president of global intellectual property, in a statement.

      November 23, 2005


       

      Share this Article!

    Back to top^